# US 2013/0273103 A1 · Polyvalent immunogen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273103 A1
- Document ID: US20130273103A1
- Status: Published application
- Kind: A1
- Application number: 13/876,830
- Filed: 2011-09-28
- Published: 2013-10-17
- Earliest claimed: 2010-09-28
- Assignees: Los Alamos National Security, LLC; Duke University
- Inventors: Hua-xin Liao; Alan S. Lapedes; Barton F. Haynes; Bette T. Korber
- Web page: https://patentgrep.com/patent/US20130273103A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates, in general, to HIV-1 and, in particular, to polyvalent immunogens suitable for use in inducing an immune response to HIV-1 in a patient, and to methods of identifying such immunogens. The invention further relates to methods of inducing an anti-HIV-1 immune response using such immunogens.

## Claims

### Claim 1

A polyvalent immunogen comprising gp140 Envs:
i) B.0040, B.6240 and C.089,
ii) B.0040, B.6240 and B.62357,
iii) CONS, B.0040 and B.6240, or
iv) CON.S, 8.0040 and C.089.

### Claim 2

A polyvalent immunogen comprising gp140 ENVS:
i) CON.S, B.63521, B.0040, B.62357, B.6240, and C.089, or
ii) CON.S, A1.con.env.03.140CF, C.con.env.03.140CF, CON.T, 8.0040 and C.089.

### Claim 3 (depends on 1)

A composition comprising the polyvalent immunogen of claim 1 and an adjuvant.

### Claim 4 (depends on 1)

A method of inducing the production in a subject of an immune response against HIV-1 comprising administering to said subject the polyvalent immunogen of claim 1 in an amount sufficient to effect said induction.

### Claim 5 (depends on 4)

The method according to claim 4 further comprising administering to said subject an adjuvant.

### Claim 6 (depends on 5)

The method according to claim 5 wherein said adjuvant is monophosphorylipid A, a TLR9 agonist, or a squalene-based adjuvant.

### Claim 7 (depends on 4)

The method according to claim 4 wherein said polyvalent immunogen is produced in said subject following introduction into said subject of a nucleotide sequence, or nucleotide sequences, encoding said polyvalent immunogen under conditions such that said nucleotide sequence, or nucleotide sequences, is/are expressed and production of said polyvalent immunogen is thereby effected,

### Claim 8 (depends on 4)

The method according to claim 4 wherein said subject is a human.

### Claim 9

Use of a polyvalent immunogen comprising gp140 Envs:
i) B.0040, B.6240 and 0.089,
ii) B.0040, B.6240 and B.62357.
iii) CON.S, B.0040 and B.6240, or
iv) CONS, B.0040 and C.089,
or nucleotide sequence, or nucleotide sequences, encoding said polyvalent immunogen,
for inducing an immune response against HIV-1 in a subject.

### Claim 10

Use of a polyvalent immunogen comprising gp140 Envs:
i) CON.S, B.63521, B.0040, B.62357, B.6240, and C.089, or
ii) CON.S, Al .con.env.03.140CF, C.con.env.03.140CF, CON.T, 8.0040 and C.089,
or nucleotide sequence, or nucleotide sequences, encoding said polyvalent immunogen,
for inducing an immune response against HIV-1 in a subject.

### Claim 11 (depends on 2)

A composition comprising the polyvalent immunogen of claim 2 and an adjuvant.

### Claim 12 (depends on 2)

A method of inducing the production in a subject of an immune response against HIV-1 comprising administering to said subject the polyvalent immunogen of claim 2 in an amount sufficient to effect said induction.

### Claim 13 (depends on 12)

The method according to claim 12 further comprising administering to said subject an adjuvant.

### Claim 14 (depends on 13)

The method according to claim 13 wherein said adjuvant is monophosphorylipid A, a TLR9 agonist, or a squalene-based adjuvant.

### Claim 15 (depends on 12)

The method according to claim 12 wherein said polyvalent immunogen is produced in said subject following introduction into said subject of a nucleotide sequence, or nucleotide sequences, encoding said polyvalent immunogen under conditions such that said nucleotide sequence, or nucleotide sequences, is/are expressed and production of said polyvalent immunogen is thereby effected.

### Claim 16 (depends on 12)

The method according to claim 12 wherein said subject is a human.
